Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
21.56
-0.47 (-2.13%)
At close: Jun 18, 2025, 4:00 PM
21.50
-0.06 (-0.28%)
After-hours: Jun 18, 2025, 7:38 PM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,204,661
Profits / Employee
$424,876
Market Cap
13.28B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GMAB News
- 2 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 2 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 3 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 4 days ago - Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - Business Wire
- 7 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 16 days ago - Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Business Wire
- 23 days ago - Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire